BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: Myelodysplastic Syndrome (MDS) Market Spotlight

February 17, 2021

Myelodysplastic syndrome (MDS) encompasses a diverse group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis and dysplasia; these disorders have an inherent tendency to transform into acute leukemia. MDS is also called bone marrow failure disorder. Healthy bone marrow generates immature blood cells (called progenitor cells), stem cells, and blast cells, which transform into mature and functional white blood cells, red blood cells, and platelets. In individuals with MDS, these stem cells may not develop into mature cells and instead accumulate in the bone marrow, or else the stem cells may have a decreased lifespan, resulting in fewer mature blood cells. Low blood cell counts, called cytopenias, are a characteristic feature of MDS, which leads to infection, spontaneous bleeding, anemia, or easy bruising. MDS is usually diagnosed in elderly patients with anemia or bi- or pancytopenia.

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Myelodysplastic Syndrome (MDS)
Back to the top Back to the top